Palma de Mallorca, November 04th, 2014 –

Laminar Pharma presented today at BIO-Europe 2014, the leading biotechnological event in Europe, held in Frankfurt (Germany) 3-5 November, the main highlights of its Phase I/IIA clinical trial with 2OHOA for the treatment of glioma and other solid tumours. The presentation was in the Next Generation track and the main results of the first 5 cohorts in the MIN-001-1203 study have been presented. No safety issues have arisen at doses of up to 8g/day while clinical benefit has been reported in two patients, one of then in a GBM patient showing a sustained Partial Response after more than 1 year of continued treatment.